Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ALLERGAN PLC
10/19 SYNDAX PHARMACEUTICALS : Expands Pipeline with Exclusive Worldwide License to Al..
10/19 ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS® Patent Decisi..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/18 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/18 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/16 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/16 ALLERGAN : Announces Settlement on RESTASIS 0.05% Patent Litigation with InnoPha..
10/13 ALLERGAN : to Present Data from More Than 20 Abstracts at the 2017 Fall Clinical..
10/12 ALLERGAN : Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) ..
10/12 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
10/11 ALLERGAN : to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical..
10/11 ALLERGAN : to Present New Dry Eye Data at the American Academy of Optometry Meet..
More most relevant news
All news about ALLERGAN PLC
10/19 ALLERGAN : Academy of Managed Care Pharmacy AMCP Foundation and Allergan Offered..
10/19 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
10/19 ALLERGAN : Announces Settlement on RESTASIS® Cyclosporine Ophthalmic Emulsion 0...
10/19 ALLERGAN : to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical..
10/19 SYNDAX PHARMACEUTICALS : Expands Pipeline with Exclusive Worldwide License to Al..
10/19 ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS® Patent Decisi..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/18 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/18 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/20 Allergan Brings The Roof Down On Its Head
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 ALLERGAN'S FROWN LINES DEEPEN : Time To Reevaluate Management
10/20 Imprimis To Challenge Allergan's Restasis With Cheaper Product
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 Imprimis Pharma to offer compounded alternatives to Allergan's Restasis; shar..
Latest Tweets
03:01aAllergan, Restasis and the Mohawks vs. the Feds: Epic fail? $AGN  
10/22Allergan PLC. $AGN is Graybill Bartz & Assoc Ltd.’s 10th Largest Position.. 
10/22Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent f.. 
10/22Allergan PLC. $AGN Receives “Outperform” Rating from Wells Fargo & Compan.. 
10/21Allergan PLC. $AGN Position Lifted by Perpetual Ltd  
More tweets
Qtime:176
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -3 984 M
Debt 2017 24 537 M
Yield 2017 1,55%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,50x
EV / Sales 2018 5,24x
Capitalization 62 943 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 241 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-10.89%62 943
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223